Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DeltEx + temozolomide
- Development stage
- Unknown
- Lead developer
- IN8bio
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intratumoral, Oral
01
Overview
DeltEx + temozolomide is a combination therapy for glioblastoma multiforme (GBM) that consists of autologous or allogeneic ex vivo expanded, activated, gene-modified γδ T cells (DeltEx drug-resistant immunotherapy, DeltEx DRI) administered in combination with temozolomide chemotherapy. The γδ T cells are genetically engineered to express O6-methylguanine-DNA methyltransferase (MGMT), which confers resistance to temozolomide-induced cytotoxicity, allowing the cells to persist in the presence of alkylating chemotherapy. This approach seeks to synergize the cytotoxic antitumor effects of temozolomide with the targeted immunotherapeutic activity of γδ T cells, which recognize and kill tumor cells via NKG2D ligand-dependent mechanisms. The DeltEx DRI cells are typically delivered intratumorally following tumor resection, with temozolomide administered systemically according to the Stupp regimen. The therapy is in phase 1b and 2 trials and is being developed for newly diagnosed and recurrent glioblastoma, with ongoing studies evaluating both autologous and allogeneic DeltEx DRI cell products[2][3][4].
- Other names
- drug-resistant immunotherapy + temozolomideDeltEx DRI + temozolomideDeltEx gd T cells + temozolomide
02
Targets
NKG2DL (NKG2D ligand family)O6-MeG (O6-methylguanine DNA lesion)
Beyond the preview
Go deeper on DeltEx + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DeltEx + temozolomide.